<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188887</url>
  </required_header>
  <id_info>
    <org_study_id>P140931</org_study_id>
    <nct_id>NCT03188887</nct_id>
  </id_info>
  <brief_title>Treatment of IgA Nephropathy According to Renal Lesions</brief_title>
  <acronym>TIGER</acronym>
  <official_title>Treatment of IgA Nephropathy According to Renal Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TIGER study (Treatment of IgA nEphropathy according to Renal lesions) is a prospective openly
      randomized controlled study.

      The main objective is to evaluate the efficacy of early corticotherapy + RAS blockade (versus
      RAS blockade alone) after two years of evolution in IgAN patients with severe histological
      lesions The study will include 122 IgAN patients, it is scheduled to start in september 2017.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, IgAN treatment recommendations are only based on clinico-biological parameters.
      Steroids therapy appears to have a major role in IgAN treatment, but previous studies
      evaluating steroids lacked of optimal control group and reproducible evaluation criteria. No
      prospective study with optimal RAS blockade had included renal pathology in patients
      selection criteria, although histological evaluation improves patients prognosis prediction.
      Until now, the lack of a reliable histological classification has precluded the use of
      histological lesions to evaluate IgAN prognosis and treatment. Given the recently identified
      major prognostic role of histological lesions in IgAN, we propose to introduce renal
      pathology to guide the treatment of IgAN in a multicenter study, using currently validated
      evaluation criteria of chronic kidney disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure at 24 months</measure>
    <time_frame>Month 24</time_frame>
    <description>Failure at 24 months will be defined as :
Proteinuria/creatinuria ratio (PCR) &gt; 0,5 g/g
or mGFR &lt; 80% of initial mGFR (or eGFR if unavailable)
or loss of more than 10 ml/min/1,73m2 of initial mGFR (or eGFR if unavailable)
or end stage renal disease (ESRD)
or renal transplantation
or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure at 6 months</measure>
    <time_frame>Month 6</time_frame>
    <description>Failure at 6 months will be defined as:
PCR &gt; 0.75 g/g
or PCR &gt; 0.5 g/g and &gt;30% of initial PCR
or eGFR &lt; 80% of initial eGFR
or ESRD
or renal transplantation
or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>Failure at 12 months will be defined as:
PCR &gt; 0.75 g/g
or PCR &gt; 0.5 g/g and &gt; 30% of initial PCR
or mGFR &lt; 80% of initial mGFR (or eGFR if unavailable)
or ESRD
or renal transplantation
or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with persistent severe histological lesions in repeat kidney biopsy at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>to compare the evolution of histological lesions between treatment groups at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of GFR at 12 months assessed as :- the absolute value of GFR - the absolute difference of GFR from the baseline - the annual degradation (ml/min /1,73m2/year) of GFR during the 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>to compare the evolution of measured GFR (mGFR) between treatment groups at 12 months (or estimated GFR (eGFR) if unavailable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of GFR at 24 months assessed as :- the absolute value of GFR - the absolute difference of GFR from the baseline - the annual degradation (ml/min /1,73m2/year) of GFR during the 24 months</measure>
    <time_frame>Month 24</time_frame>
    <description>to compare the evolution of measured GFR (mGFR) between treatment groups at 24 months (or estimated GFR (eGFR) if unavailable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of proteinuria assessed as : - the absolute value of proteinuria at 12 and 24 months - the absolute difference of proteinuria from baseline at 12 and 24 months</measure>
    <time_frame>Month 12 and 24</time_frame>
    <description>to compare the evolution of proteinuria in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 scale at 12 months</measure>
    <time_frame>Month 12</time_frame>
    <description>to compare the quality of life in each therapeutic group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 scale at 24 months</measure>
    <time_frame>Month 24</time_frame>
    <description>to compare the quality of life in each therapeutic group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects</measure>
    <time_frame>Month 24</time_frame>
    <description>to assess the tolerance of treatments in each therapeutic group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis markers of failure at 24 months</measure>
    <time_frame>Month 24</time_frame>
    <description>Clinical, histological, and biological data (including PCR ratio, eGFR and mGFR, renal histological lesions) will be compared between patients with or without failure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Renin Angiotensin system (RAS) blockade.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXPERIMENTAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corticotherapy + RAS blockade treatment. Drug injection (intravenous) + tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticotherapy</intervention_name>
    <description>3 IV pulses steroids followed by oral steroids for 4 months</description>
    <arm_group_label>EXPERIMENTAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renin Angiotensin system (RAS) blockade</intervention_name>
    <description>treatment with Renin angiotensin system (RAS) blockade</description>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_label>EXPERIMENTAL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 years

          2. IgAN diagnosed on renal biopsy &lt; 45 days

          3. PCR ratio &gt;0.75 g/g (within 15 days before or after the renal biopsy)

          4. Renal biopsy with at least 8 glomeruli, disclosing at least 2 criteria among:

               -  mesangial proliferation (according to Oxford criteria)

               -  endocapillary proliferation (according to Oxford criteria)

               -  tubulointerstitial fibrosis (according to Oxford criteria) &gt;25% of the biopsy

               -  segmental glomerulosclerosis (according to Oxford criteria)

               -  ≥10% cellular/fibrocellular crescents.

          5. Patient with Social Security System Insurance

          6. Patient having signed an informed consent

        Exclusion Criteria:

          1. &gt;30% increase of serum creatinine within 15 days after starting RAS blockade therapy

          2. &gt;50% cellular/fibrocellular crescents, or &gt;50% tubulointerstitial fibrosis or &gt;50%
             globally sclerotic glomeruli

          3. &gt;50% plasma creatinine increase within the last 3 months before the renal biopsy

          4. Nephrotic syndrome with minimal change disease and IgA deposits

          5. eGFR &lt;20 ml/min/1,73m2 (CKD-EPI formula) within 15 days before or after the renal
             biopsy

          6. Uncontrolled blood pressure (Systolic blood pressure &gt;180 mmHg or diastolic blood
             pressure &gt; 110 mmHg)

          7. Previous corticosteroids treatment (&gt;20 mg/d during more than 15 days, within the last
             3 months before the renal biopsy)

          8. Pregnancy or breast feeding or women without sufficient contraception

          9. Secondary known forms of IgAN

         10. Henoch-Schoenlein purpura

         11. Additional other chronic renal disease

         12. Contraindication for immunosuppressive therapy, including active intestinal bleeding,
             active gastric or duodenal ulcer; active infection; any malignancy in a last years
             before the inclusion; severe psychiatric disease; living vaccines; anti-inflammatory
             dosages of acetylsalicylic acid

         13. Contraindication for RAS blockade therapy

         14. Known allergy or intolerance to corticoids or lactose

         15. Organ transplant patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique JOLY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric ALAMARTINE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique JOLY, MD, PhD</last_name>
    <phone>+33 1 44 49 54 12</phone>
    <email>dominique.joly@nck.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra COLAS</last_name>
    <phone>01 71 19 64 32</phone>
    <email>sandra.colas@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker Enfants-malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique JOLY, MD, PhD</last_name>
      <phone>+33 1 44 49 54 12</phone>
      <email>dominique.joly@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NIgA</keyword>
  <keyword>Kidney biopsy</keyword>
  <keyword>GFR</keyword>
  <keyword>Corticotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

